Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial

Acknowledgments We would like to thank the thousands of patients who participated in this trial. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 177 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, NHS Blood and Transplant, the Scottish National Blood Transfusion Service, the Welsh Blood Service, the Northern Ireland Blood Transfusion Service, Public Health England, Department of Health & Social Care, the Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, the Secure Anonymised Information Linkage at University of Swansea, Swansea, UK, and the NHS in England, Scotland, Wales and Northern Ireland. The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation (UKRI) and NIHR (MC_PC_19056), by the Department of Health and Social Care (DHSC), UKRI, and NIHR COVID-19 Rapid Response Grant (COV19-RECPLA), and by core funding provided by NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill & Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, NHS Blood and Transplant Research and Development Funding, EU's Horizon 2020 research and innovation programme (SUPPORT-E - 101015756), and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from UK Medical Research Council (MC_UU_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. AbbVie contributed some supplies of lopinavir–ritonavir for use in this trial. Tocilizumab was provided free of charge for this trial by Roche. REGN-COV2 was provided free of charge for this trial by Regeneron. The collection of plasma was funded by the DHSC through core funding and funding under COVID-19 and EU SoHo Grant. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, NHS Blood and Transplant, the DHSC, or the EU. Funding UK Research and Innovation (Medical Research Council) and National Institute of Health Research. The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the RECOVERY trial is provided in the appendix (pp 2–28)Peer reviewedPublisher PD